Mizuho lowered the firm’s price target on ResMed (RMD) to $300 from $310 and keeps an Outperform rating on the shares following the fiscal Q1 report. The firm says GLP-1s are not presenting a headwind yet for ResMed while its US competition is stable.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: